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To the Editor
Maxillary osteonecrosis (MON) associated to bisphos-
phonate (BP) use is a slow-evolving (over 6 weeks) form 
of chronic osteomyelitis characterized by the exposure 
of mandibular or maxillary bone seen in patients ad-
ministered present or past BP therapy, and who have not 
been subjected to maxillofacial radiotherapy and show 
no evidence of metastatic disease (1).
Different studies have identified a series of risk factors 
for BP-induced MON, including the use of nitrogenated 
BPs, the duration of treatment, concomitant corticoid 
use, or dental surgical procedures. A number of hy-
potheses have been proposed in an attempt to explain 
BP-induced MON. At tissue level, some authors con-
sider MON to be due to diminished bone turnover, with 
the inhibition of bone resorption, while at cellular level 
other investigators postulate an inhibition of osteoclast 
recruitment and activity at bone surface level – favoring 
apoptosis. Interaction would take place with a receptor 
or intracellular enzyme within the osteoclasts, resulting 
in the inhibition of ATP-dependent enzymes. Likewise, 
and although still subject to controversy, an antiang-
iogenic effect is observed, acting mainly upon the soft 
tissues - with no evidence to suggest that this effect oc-
curs during the bone remodeling process (2). 
Different antineoplastic drugs are presently used in 
which the mechanism of action involves the suppres-
sion of some stage of angiogenesis. Tumor angiogenesis 
is characterized by the proliferation of blood vessels 
within the neoplasm, transporting oxygen and nutrients 
to the tumor cells and facilitating tumor growth. 
If the inhibition of angiogenesis is one of the factors 
related to the production of MON, then antineoplastic 
drugs that act via an antiangiogenic mechanism could 
contribute to trigger or facilitate MON in patients treat-
ed with BPs. 
Bevacizumab (Avastin®) is a monoclonal antibody that 
binds to vascular endothelial growth factor (VEGF) 
-a key element in vasculogenesis and angiogenesis- 
thereby preventing VEGF from binding to its receptors. 
Such neutralization of the biological activity of VEGF 
induces the regression of tumor vascularization, nor-
malizing tumor residual vascularization, and inhibiting 
tumor neovascularization. Tumor growth is inhibited as 
a result. 
Different authorsd have related the use of bevacizumab 
to an increased risk of MON in patients treated with 
BPs (3-5), with prevalences of up to 16% in patients 
administered bevacizumab and BPs versus only 1% 
in patients treated only with BPs (3). It was postulated 
that bevacizumab and other antiangiogenic drugs could 
exert an inducing effect favoring the development of 
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MON. Posteriorly, it was seen that bevacizumab could 
lead to MON in patients that had not been treated with 
BPs. To date, three cases have been reported of MON in 
patients not administered BPs, attributable to treatment 
with bevacizumab (6,7). These cases are summarized 
in (Table 1). 
On the other hand, sunitinib (Sutent®) is an antineoplas-
tic drug that inhibits multiple tyrosine kinase receptors 
implicated in tumor growth, neoangiogenesis and meta-
static cancer progression. Among other receptors, this 
drug inhibits the range of VEGF receptors (VEGFR 1,2 
and 3).
Likewise, sunitinib was initially suggested to be able 
to induce MON (8), and was posteriorly linked to MON 
in a clinical case (9). The latter corresponded to a 59-
year-old woman diagnosed with renal carcinoma that 
had metastasized to the lungs, and who received BP for 
6 months. Posteriorly, after three months of treatment 
with sunitinib, she developed MON. Extension of su-
nitinib for another three months was decided, and the 
MON worsened considerably. On suspending the treat-
ment, the osteonecrosis stabilized and improved. After 
5 months without treatment, her lung metastases pro-
gressed, and sunitinib was reintroduced – MON reap-
pearing as a result.
Other marketed drugs with antiangiogenic activity that 
have not been linked to date to the induction of MON 
include sorafenib, cetuximab and panitumumab. On 
the other hand, a range of new molecules that act upon 
some of the phases of angiogenesis are currently in the 
investigational stage. 
It is necessary to identify all the risk factors that may 
influence the development of MON, with a view to pre-
venting the disorder. Such factors must be taken into 
consideration before treatment (10), since to date there 
is no fully satisfactory management option for estab-
lished MON.
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Sex Age Diagnosis Dosage No. Cycles 
Time to 
appearance Size Treatment Resolution Infection
Dental
surgery
F 51 Breast cancer 15 mg/kg/21 days 8 30 weeks 1x1 mm 
Curettage + 
CHX YES YES YES 
F 33 Glioblastoma multiforme 
10 mg/kg/14 
days 6 13 weeks 1x2 cm None YES NO NO 
F 63 Breast cancer NA NA 8 weeks NA Curettage YES YES YES 
Table 1. Description of the cases of maxillary osteonecrosis induced by bevacizumab.
NA - information not available; CHX – chlorhexidine; F=female.
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